PolyMedix, Inc. has orthodox a notice of no protestation from Health Canada for the Company's
Clinical Trial Application ("CTA") for its defensin mimetic antibiotic compound, PMX-30063.
This notice of no squawk allows for the initiation of human clinical ...
(more)